Federal Trade Commission Challenges Illumina’s Proposed Acquisition of Pacific Biosciences

  • 📰 WSJ
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

The Federal Trade Commission is challenging Illumina’s proposed acquisition of Pacific Biosciences of California, a $1.2 billion deal in the life-sciences industry

WASHINGTON—The Federal Trade Commission on Tuesday challenged Illumina Inc.’s. proposed acquisition of Pacific Biosciences of California, a $1.2 billion deal in the life-sciences industry.

The FTC is bringing an administrative lawsuit alleging the biotech acquisition would allow Illumina to unlawfully maintain a monopoly in next-generation DNA sequencing by eliminating PacBio as a nascent competitor.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Digital banking app MoneyLion is launching stock-trading in 2020 - Business InsiderMoneyLion, an online lending startup that raised over $200 million touting itself as an affordable banking option, is adding stock-trading in 2020
Source: BusinessInsider - 🏆 729. / 51 Read more »

DuPont chairman says deal with IFF gives new company 'double the R&D' of competitorsInternational Flavors & Fragrances is merging with DuPont's nutrition and biosciences unit, creating a $45.4 billion consumer goods giant. when do these CEO's lose their jobs for stocks which under perform greatly? $IFF stock been awful in a huge stock market year. Accountability is needed.
Source: CNBC - 🏆 12. / 72 Read more »